研究者

J-GLOBAL ID：201601015663220480 更新日: 2021年10月20日

河野吉昭

カワノヨシアキ | yoshiaki kawano

所属機関・部署：
論文 (19件)：

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, et al. Prognosis of metastatic renal cell carcinoma with first-line Interferon-α therapy in the era of molecular-targeted therapy. Cancer science. 2016. 107. 7. 1013-7
Takanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, Hirotake Tsukamoto, Mitsugu Fujita, Yoichi Saito, Kenichiro Tanoue, Yutaka Kasejima, Yutaka Sugiyama, Yoshiaki Kawano, et al. CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma. ONCOLOGY LETTERS. 2016. 11. 3. 1911-1916
Masatoshi Eto, Yoshiaki Kawano, Yoshihiko Hirao, Koji Mita, Yoichi Arai, Taiji Tsukamoto, Katsuyoshi Hashine, Akio Matsubara, Tomoaki Fujioka, Go Kimura, et al. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC CANCER. 2015. 15. 667
Takanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, Ario Takeuchi, Yoshehiro Maeda, Kenichiro Tanoue, Yoshiaki Kawano, Mamoru Harada, Motohiro Takeya, Masatoshi Eto. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. ONCOLOGY REPORTS. 2015. 33. 6. 2947-2953
Yoshihiro Maeda, Yoshiaki Kawano, Yoshihiro Wada, Junji Yatsuda, Takanobu Motoshima, Yoji Murakami, Ken Kikuchi, Takahisa Imamura, Masatoshi Eto. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. ONCOLOGY REPORTS. 2015. 33. 4. 1844-1850

もっと見る

MISC (1件)：

Y. Kawano, M. Kitaoka, Y. Hamada, M. M. Walker, J. Waxman, R. M. Kypta. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. ONCOGENE. 2006. 25. 49. 6528-6537

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

TOP

BOTTOM